Moderna Inc said on Monday it had dosed the first patients in an early-stage study of a new COVID-19 vaccine candidate for evaluation as a next-generation shot.
The company said its new candidate, mRNA-1283, could potentially be stored in refrigerators instead of freezers, making it easier to distribute, especially in developing countries.
The early-stage study will assess the safety and immunogenicity of mRNA-1283 at three dose levels, and will be given to healthy adults either as a single dose or in two doses 28 days apart, the company said.
Last week, Moderna began dosing the first participants in a study testing its COVID-19 booster vaccine candidates.
(Reporting by Manojna Maddipatla and Vishwadha Chander in Bengaluru; Editing by Shailesh Kuber and Anil D'Silva)
Click here to read the Mint ePaperMint is now on Telegram. Join Mint channel in your Telegram and stay updated with the latest business news.